Original Research
Published on 30 May 2025
Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China
in Health Economics
- 843 views
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Published on 30 May 2025
in Health Economics
Original Research
Accepted on 29 May 2025
in Health Economics
Original Research
Published on 29 May 2025
in Health Economics
Original Research
Accepted on 28 May 2025
in Health Economics
Original Research
Published on 27 May 2025
in Health Economics
Original Research
Published on 27 May 2025
in Health Economics
Original Research
Published on 27 May 2025
in Health Economics
Original Research
Published on 27 May 2025
in Health Economics